Biopsy-derived organoids, accurate models of disease, are used to search for new drugs. Now, results obtained by a study led ...

Investigators developed and validated new PSMA-PET-based nomograms for prognostication across prostate cancer stages to help guide management.

BDRX READ THE FULL BDRX RESEARCH REPORT We are initiating coverage of Biodexa Pharmaceuticals, PLC (NASDAQ: BDRX) with a valuation of $7.00. Biodexa is a clinical-stage GI oncology company focused on ...

Scientists are using proteomics to decode the complex biology of endometriosis, revealing protein patterns that could enable earlier, non-invasive diagnosis and more personalized care.

FDA review uncertainty, failed phase 3 for ersodetug in HI, high-risk upLIFT trial, tight cash runway—read more macro ...

Percutaneous thermal ablation shows that its 90-day mortality rate is nearly zero, and its major complication rate is only about 3%, which again shows that this treatment modality has a high ...

Fear of dementia is rising almost as fast as the condition itself. And where fear grows, so does a market promising protection. Among the most popular offerings is Ginkgo biloba, a centuries-old ...

Antibody–drug conjugates (ADCs) represent one of the most transformative advances in precision oncology over the past two decades and are increasingly positioned to replace conventional chemotherapy ...

Rare cancers encompass a heterogeneous group of malignancies characterized by low incidence and prevalence but, often, disproportionately high mortality ...

The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

Large randomized trial makes case for non-inferiority versus surgery; smaller study falls ...

This article discusses the best growth stocks to buy right now.